The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous systemincluding psychiatric drugsare assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine’s (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA’s new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future.
Acquista questo ebook e ricevine 1 in più GRATIS!
Lingua Inglese ● Formato EPUB ● Pagine 88 ● ISBN 9780309186483 ● Editore Bruce Altevogt & Miriam Davis ● Casa editrice National Academies Press ● Pubblicato 2010 ● Scaricabile 3 volte ● Moneta EUR ● ID 7149718 ● Protezione dalla copia Adobe DRM
Richiede un lettore di ebook compatibile con DRM